Abstract
Several beta-emitting radiopharmaceuticals, including 89Sr-chloride, 186Re-hydroxyethylidene diphosphonate, and 153Sm-ethylene diamine tetramethylene phosphonate, have been developed for palliation of bone pain due to metastases. 223Ra dichloride is a novel bone-seeking alpha emitter used for treatment of CRPC in patients with bone metastases. It is a calcium-mimetic solution that selectively targets area of increased bone turnover in bone metastases. First clinical studies with 223Ra started in 2012. This chapter aims to describe the employment of 223Ra-dichloride in clinical setting, by analyzing the different clinical trials and future perspectives for this targeted nuclear medicine therapy.
The authors declared that they have obtained the permission for any previously published material used in the chapter.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- 153Sm:
-
Samarium-153
- 186Re:
-
Rhenium-186
- 223Ra:
-
Radium-223
- 89Sr:
-
Strontium-89
- ALARA:
-
As low as reasonably achievable
- ALP:
-
Alkalinephosphate
- ALSYMPCA:
-
ALpharadin in SYMPtomatic Prostate CAncer
- CRPC:
-
Castrate-resistant prostate cancer
- CT:
-
Computed tomography
- EBRT:
-
External beam radiotherapy
- Gy:
-
Gray
- LET:
-
Linear energy transfer
- MBq:
-
MegaBequerel
- MDP:
-
Methyl disphosphonate
- Mev:
-
Megaelectronvolt
- mSv:
-
Milli-sievert
- NIST:
-
National Institute of Standard and Technology
- PET:
-
Positron emission tomography
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
Carrasquillo JA, O’Donoghue JA, Pandit-Taskar N. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant-metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2003;40:1384–93.
Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8:587–94.
Nilsson SL, Larsen RH, Foss SD, et al. First clinical experience with a-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11:4451–9.
Nilsson S, Strang P, Aksnes A, et al. A randomized, dose-response, multicentre phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48:678–86.
Parker C, Pascoe S, Chodacki A, et al. A randomized. Double-blind, dose-finding, multicenter phase 2 trial or radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013;63(2):189–97.
Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15:738–46.
Pacilio M, Ventroni G, Cassano B, et al. A case report of image-based dosimetry of bone metastases with Alpharadin (223Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up. Ann Nucl Med. 2016;30:163–8.
Pacilio M, Ventroni G, De Vincentis G, et al. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride. Eur J Nucl Med Mol Imaging. 2016;43(1):21–33.
Hindorf C, Chittenden S, Aksnes A-K, et al. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nucl Med Commun. 2012;33:726–32.
AIFM-AIMN. Linee guida AIFM-AIMN per l’utilizzo terapeutico del 223-Ra. 2014.
Stabin S a. Health Phys. 2012;102:271–91.
Nilsson S, Balteskard L, Foss SD, et al. Phase I study of Alpharadin2 (223Ra), and a-emitting bone-seeking agent in cancer patients with skeletalmetastases. Eur J Nucl Med Mol Imaging. 2004;31:S290/no 370 [abstract].
Carrasquillo JA, J. A. O’Donoghue, Pandit-Taskar N, et al. Phase I pharmacokinetic (PK) and biodistribution study of radium-223 chloride in patients with castration resistant prostate cancer (CRPC) metastatic to bone. 46th annu Meet am Soc Clin oncol (aSCo) (June 4–8, Chicago) 2010, abstratc 4680. 2010.
Chittenden S, Hindorf C, Parker C, et al. A phase 1, open-label study of the biodistribution, pharmacokinetics, and dosimetry of 223Ra-dichloride in patients with hormone-refractory prostate cancer and skeletal metastases. J Nucl Med. 2015;56:1304–9.
Lassmann M, Nosske D. Dosimetry of 223Ra-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging. 2013;40:207–12.
Pacilio M, Cassano B, et al. Gamma camera calibrations for the Italian multicentre study for lesion dosimetry in 223Ra therapy of bone metastases. Phys Med. 2017 Sep;41:117–23. https://doi.org/10.1016/j.ejmp.2017.04.019.
Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.
Vogelzang NJ, Coleman RE, Michalski JM, et al. Hematologic safety of radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the ALSYMPCA trial. Clin Genitourin Cancer. 2017;15(1):42–52.e8.
Saad F, Carles J, Gillessen S, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17:1306–16.
Sartor AO, Heinrich D., Mariados N, et al. Radium-223 (Ra-223) re-treatment (Re-tx): first experience from an international, multicenter, prospective study in patients (Pts) with castration-resistant prostate cancer and bone metastases (mCRPC). Genitourinary Cancers Symposium 2016. 2016.
Morris MJ, HJ Hammers, Sweeney C, et al. Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): a phase I prostate Cancer clinical trials consortium study. ASCO Annual Meeting 2013. 2013.
Wilson JM, Parker C. The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer. Expert Rev Anticancer Ther. 2016;16:911–8.
Dalla Volta A, Formenti A, Berruti A. Higher risk of fragility fractures in prostate cancer patients treated with combined radium-223 and abiraterone: prednisone may be the culprit. Eur Urol. 2019;75(6):894–5. https://doi.org/10.1016/j.eururo.2019.01.026.
Dizdarevic S, Petersen PM, Essler M, Versari A, Bourre J-C, la Fougere C, et al. Interim analysis of the REASSURE (Radium-223 alpha emitter agent in non-intervetional safety study in mCRPC population for long-term evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice. Eur J Nucl Med Mol Imaging. 2019;46:1102. https://doi.org/10.1007/s00259-019-4261-y.
Evangelista L, Zorz A. Re: response assessment of 223Ra treatment: should a fluorocholine PET/CT be performed? Clin Nucl Med. 2018;43(11):867–8.
García Vicente AM, Soriano Castrejón Á, Alvarez Cabellos R, Sanchez Gil B, Mohedano Mohedano N. Response assessment of 223Ra treatment: should a fluorocholine PET/CT be performed? Clin Nucl Med. 2017;42(10):761–5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Evangelista, L., Zorz, A. (2020). The Bone Pathway: 223Ra-Dichloride. In: Calabria, F., Schillaci, O. (eds) Radiopharmaceuticals. Springer, Cham. https://doi.org/10.1007/978-3-030-27779-6_10
Download citation
DOI: https://doi.org/10.1007/978-3-030-27779-6_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-27778-9
Online ISBN: 978-3-030-27779-6
eBook Packages: MedicineMedicine (R0)